CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer

Journal of Clinical Investigation

Volumn 126, Issue 7, 2016, Pages 2610-2620

  Weiskopf, Kipp ^a,b   Jahchan, Nadine S ^a,b   Schnorr, Peter J ^a,b   Cristea, Sandra ^a,b   Ring, Aaron M ^a,b   Maute, Roy L ^a,b   Volkmer, Anne K ^a,b,c   Volkmer, Jens Peter ^a,b   Liu, Jie ^a,b   Lim, Jing Shan ^a,b   Yang, Dian ^a,b   Seitz, Garrett ^a,b   Nguyen, Thuyen ^a,b   Wu, Di ^a,b   Jude, Kevin ^a,b   Guerston, Heather ^a   Barkal, Amira ^a,b   Trapani, Francesca ^d   George, Julie ^e   Poirier, John T ^f   Gardner, Eric E ^f   Miles, Linde A ^f   De Stanchina, Elisa ^f   Lofgren, Shane M ^a,b   Vogel, Hannes ^b,g   Winslow, Monte M ^a,g   Dive, Caroline ^d   Thomas, Roman K ^a,e   Rudin, Charles M ^f   Van De Rijn, Matt ^g,h   Majeti, Ravindra ^a,b   Garcia, K Christopher ^a,b   Weissman, Irving L ^a,b,g   Sage, Julien ^a,b   more..

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITY OF COLOGNE   (Germany)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD47 ANTIGEN; HU5F9 G4 ANTIBODY; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; NERVE CELL ADHESION MOLECULE; UNCLASSIFIED DRUG; CD47 PROTEIN, HUMAN; CD47 PROTEIN, MOUSE; CD56 ANTIGEN; CYTOKINE; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN RECEPTOR; NCAM1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY REACTION; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD47 GENE; CLINICAL ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOKINE RELEASE; GENE INACTIVATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; MACROPHAGE; MOUSE; MOUSE MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SMALL CELL LUNG CANCER; TUMOR GENE; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; METABOLISM; PROCEDURES; SIGNAL TRANSDUCTION; SMALL CELL LUNG CARCINOMA; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD47; ANTIGENS, CD56; CELL LINE, TUMOR; CYTOKINES; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MACROPHAGES; MICE; PHAGOCYTOSIS; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; SMALL CELL LUNG CARCINOMA;

EID: 84978381315     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI81603     Document Type: Article

References (54)

1. Park KS, et al. Characterization of the cell of origin for small cell lung cancer. Cell Cycle. 2011; 10 (16):2806-2815.
2. Sutherland KD, Proost N, Brouns I, Adriaensen D, Song JY, Berns A. Cell of origin of small cell lung cancer: inactivation of Trp53 and rb1 in distinct cell types of adult mouse lung. Cancer Cell. 2011; 19 (6):754-764.
3. van Meerbeeck JP, Fennell DA, De Ruysscher DK Small-cell lung cancer. Lancet. 2011; 378 (9804):1741-1755.
4. Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2015; 121 (5):664-672.
5. Pardoll DM The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12 (4):252-264.
6. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Ann Rev Med. 2014; 65:185-202.
7. Jaiswal S, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009; 138 (2):271-285.
8. Majeti R, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009; 138 (2):286-299.
9. Willingham SB, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012; 109 (17):6662-6667.
10. Weiskopf K, et al. Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies. Science. 2013; 341 (6141):88-91.
11. Weiskopf K, Weissman IL. Macrophages are critical effectors of antibody therapies for cancer. MAbs. 2015; 7 (2):303-310.
12. Zhao XW, et al. CD47-signal regulatory proteinalpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A. 2011; 108 (45):18342-18347.
13. Theocharides AP, et al. Disruption of SIRPalpha signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts. J Exp Med. 2012; 209 (10):1883-1899.
14. Chao MP, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010; 142 (5):699-713.
15. Eerola AK, Soini Y, Paakko P. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin Cancer Res. 2000; 6 (5):1875-1881.
16. Peifer M, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012; 44 (10):1104-1110.
17. Rudin CM, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012; 44 (10):1111-1116.
18. Pedersen N, et al. Transcriptional gene expression profiling of small cell lung cancer cells. Cancer Res. 2003; 63 (8):1943-1953.
19. Hodgkinson CL, et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med. 2014; 20 (8):897-903.
20. Liu J, et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS One. 2015; 10 (9):e0137345.
21. Hatherley D, Graham SC, Turner J, Harlos K, Stuart DI, Barclay AN. Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47. Mol Cell. 2008; 31 (2):266-277.
22. Shultz LD, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005; 174 (10):6477-6489.
23. Leong TL, et al. Genomic characterisation of small cell lung cancer patient-derived xenografts generated from endobronchial ultrasound-guided transbronchial needle aspiration specimens. PLoS One. 2014; 9 (9):e106862.
24. Daniel VC, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009; 69 (8):3364-3373.
25. Nakazawa K, et al. Specific organ metastases and survival in small cell lung cancer. Oncol Lett. 2012; 4 (4):617-620.
26. Schaffer BE, et al. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res. 2010; 70 (10):3877-3883.
27. Park KS, et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med. 2011; 17 (11):1504-1508.
28. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 2013; 229 (2):176-185.
29. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012; 122 (3):787-795.
30. Murray PJ, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014; 41 (1):14-20.
31. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science. 2013; 341 (6151):1192-1198.
32. Fargion S, et al. Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies. Cancer Res. 1986; 46 (5):2633-2638.
33. Jackson D, Waibel R, Weber E, Bell J, Stahel RA. CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas. Cancer Res. 1992; 52 (19):5264-5270.
34. Aletsee-Ufrecht MC, Langley K, Rotsch M, Havemann K, Gratzl M. NCAM: a surface marker for human small cell lung cancer cells. FEBS Lett. 1990; 267 (2):295-300.
35. Teicher BA Targets in small cell lung cancer. Biochem Pharmacol. 2014; 87 (2):211-219.
36. Schultheis AM, et al. PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer. 2015; 51 (3):421-426.
37. Lambert JM Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol. 2005; 5 (5):543-549.
38. Whiteman KR, et al. Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. MAbs. 2014; 6 (2):556-566.
39. Tseng D, et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A. 2013; 110 (27):11103-11108.
40. Liu X, et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 2015; 21 (10):1209-1215.
41. Leidi M, et al. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol. 2009; 182 (7):4415-4422.
42. Zhang M, et al. Anti-CD47 Treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo. PLoS ONE. 2016; 11 (4):e0153550.
43. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014; 6:13.
44. Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer. 2007; 109 (2):170-179.
45. Chao MP, et al. Calreticulin is the dominant prophagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2010; 2 (63):63ra94.
46. Pang WW, et al. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci U S A. 2013; 110 (8):3011-3016.
47. Sockolosky JT, et al. Durable antitumor responses to CD47 blockade require adaptive immune stimulation [published online ahead of print April 18, 2016]. Proc Natl Acad Sci U S A. doi:10.1073/pnas.1604268113.
48. Marabelle A, et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest. 2013; 123 (6):2447-2463.
49. Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013; 500 (7463):415-421.
50. George J, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015; 524 (7563):47-53.
51. Reck M, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013; 24 (1):75-83.
52. Brahmer JR, Pardoll DM. Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res. 2013; 1 (2):85-91.
53. Wargo JA, Cooper ZA, Flaherty KT. Universes collide: combining immunotherapy with targeted therapy for cancer. Cancer Discov. 2014; 4 (12):1377-1386.
54. Barretina J, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483 (7391):603-607.